Eva Wesley, Author at Born2Invest

Eva Wesley

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.

Born2Invest uses cookies in order to improve your experience and make further customizations to how we present our content. By continuing to use our website, you accept and give your consent to our practices as described in the following: our revised Privacy Policy, Cookie Policy, and Terms of Use.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Born2Invest

Eva Wesley

Stories By Eva Wesley

Biotech’s Comeback: AI, M&A, and Innovation Drive New Growth

BioSpain 2025 Will Address Advances in Gene Therapies, mRNA Vaccines and Crispr-Cas

Amadix Receives 15 Million Euros from the EIB for Research

Vytrus Biotech Achieves 5 Million Euros in Turnover and 2 Million EBITDA in 2024

KOA Biotech closes a 2M round led by Swanlaab

Akribion Therapeutics Secures €8M to Advance CRISPR-Based Cell Depletion Technology

AbbVie and Simcere Zaiming Partner on Trispecific Antibody for Multiple Myeloma in $1.055B Deal

Owkin and Servier Challenge Glioblastoma with the Power of AI

Benchling Report: AI and Automation Reshaping Biopharma R&D

Flomics Biotech Develops RNA-Based Blood Test for Early Cancer Detection